NAS:TCON (USA) Also trade in: Germany

TRACON Pharmaceuticals Inc

$ 0.73 0 (0.68%)
Volume: 71,789 Avg Vol (1m): 462,021
Market Cap $: 21.85 Mil Enterprise Value $: -3,710,000.00
P/E (TTM): 0.00 P/B: 1.48
Earnings Power Value -6.1
Net Current Asset Value 0.46
Tangible Book 0.5
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 2/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 4.93
Cash-To-Debt ranked lower than
57.70% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
TCON: 4.93
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.93, Med: 5.18, Max: 10000
Current: 4.93
0.93
10000
Debt-to-Equity 0.44
Debt-to-Equity ranked higher than
63.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
TCON: 0.44
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.28, Med: 0.29, Max: 0.51
Current: 0.44
-0.28
0.51
Debt-to-EBITDA -0.19
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
TCON: -0.19
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.45, Med: -0.35, Max: -0.19
Current: -0.19
-1.45
-0.19
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -7.88
DISTRESS
GREY
SAFE
Beneish M-Score -99999999.99
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 15.94%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -1123.80
Operating Margin ranked lower than
56.44% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
TCON: -1123.8
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -1158, Med: -296.9, Max: -171.73
Current: -1123.8
-1158
-171.73
Net Margin % -1126.93
Net Margin ranked lower than
56.82% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
TCON: -1126.93
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -1165.3, Med: -308.83, Max: -189.24
Current: -1126.93
-1165.3
-189.24
ROE % -117.18
ROE ranked lower than
69.67% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
TCON: -117.18
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -181.94, Med: -91.07, Max: -84.3
Current: -117.18
-181.94
-84.3
ROA % -69.82
ROA ranked lower than
64.48% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
TCON: -69.82
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -306.48, Med: -54.42, Max: -33.55
Current: -69.82
-306.48
-33.55
ROC (Joel Greenblatt) % -64834.62
ROC (Joel Greenblatt) ranked lower than
92.47% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
TCON: -64834.62
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -64834.62, Med: -23496.77, Max: -10562.39
Current: -64834.62
-64834.62
-10562.39
3-Year Total Revenue Growth Rate -27.60
3-Year Revenue Growth Rate ranked higher than
76.65% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
TCON: -46.2
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
N/A
3-Year Total EBITDA Growth Rate -14.00
3-Year EBITDA Growth Rate ranked lower than
78.68% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
TCON: 15.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -28.1, Med: -18.65, Max: 15.1
Current: 15.1
-28.1
15.1
3-Year EPS w/o NRI Growth Rate 16.10
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
TCON: 16.1
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -4.2, Max: 16.1
Current: 16.1
0
16.1

» TCON's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:TCON

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325411    SIC : 2836
Compare ROCO:4195 TSX:BLU NAS:PTIE NAS:PLXP NAS:CLSN WAR:PHR NAS:VVUS LSE:C4XD ASX:IMC NAS:CYTR OTCPK:QBIO OSTO:ENZY NAS:PRTO ASX:IMM AMEX:OCX OSTO:SENZA OTCPK:DYAI ROCO:4109 OTCPK:VBIO NAS:CAPR
Traded in other countries T05.Germany
Address 4350 La Jolla Village Drive, Suite 800, San Diego, CA, USA, 92122
TRACON Pharmaceuticals Inc is a U.S based clinical stage biopharmaceutical company which focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its product candidate TRC105 is an endoglin antibody, for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor, or VEGF, pathway.

Ratios

Current vs industry vs history
PB Ratio 1.48
PB Ratio ranked higher than
79.94% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
TCON: 1.48
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.86, Med: 2.74, Max: 5.1
Current: 1.48
0.86
5.1
EV-to-EBIT 0.12
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
TCON: 0.12
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -10.6, Med: -1.4, Max: 0.7
Current: 0.12
-10.6
0.7
EV-to-EBITDA 0.12
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
TCON: 0.12
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -10.6, Med: -1.4, Max: 0.7
Current: 0.12
-10.6
0.7
EV-to-Revenue -1.25
EV-to-Revenue ranked higher than
92.74% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
TCON: -1.25
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -4.7, Med: 5.7, Max: 19.1
Current: -1.25
-4.7
19.1
Current Ratio 2.44
Current Ratio ranked higher than
53.54% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
TCON: 2.44
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.16, Med: 3.57, Max: 6.01
Current: 2.44
1.16
6.01
Quick Ratio 2.44
Quick Ratio ranked higher than
55.49% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
TCON: 2.44
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.16, Med: 3.57, Max: 6.01
Current: 2.44
1.16
6.01

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -30.30
3-Year Share Buyback Rate ranked lower than
50.88% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
TCON: -30.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -48.5, Med: -32.85, Max: -13.9
Current: -30.3
-48.5
-13.9

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 1.46
Price-to-Tangible-Book ranked higher than
85.01% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
TCON: 1.46
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.88, Med: 2.84, Max: 4.9
Current: 1.46
0.88
4.9
Earnings Yield (Joel Greenblatt) % 847.63
Earnings Yield (Greenblatt) ranked lower than
94.91% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
TCON: 847.63
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -3142.5, Med: -62.1, Max: 13355.9
Current: 847.63
-3142.5
13355.9

More Statistics

Revenue (TTM) (Mil) $ 3
EPS (TTM) $ -1.13
Beta 2.9
Volatility % 100.35
52-Week Range $ 0.5 - 3.2
Shares Outstanding (Mil) 29.94

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N